Page 5 - Diabetes

India among top 10 countries with most cases of Type 1 diabetes: Study

An estimated 8.4 million people were living with Type 1 Diabetes across the globe in 2021, and India was among the top ten countries with highest prevalence of the disease, according to a modelling study published in The Lancet Diabetes & Endocrinology journal. This number is predicted to increase to 13.5-17.4 million people living with Type 1 Diabetes (T1D) by 2040, the resaerchers said. "Given that prevalence of people with T1D is projected to increase in all countries to up to 17.5 million cases in 2040, our results provide a warning for substantial negative implications for societies and healthcare systems," said Professor Graham Ogle, one of the authors of the study, from the University of Sydney, Australia. "There is an opportunity to save millions of lives in the coming decades by raising the standard of care for T1D and increasing awareness of the signs and symptoms of T1D to enable a 100 per cent rate of diagnosis in all countries," Ogle said. Researchers modelled data on

Govt launches diabetes drug Sitagliptin, its combinations at Rs 60 per pack

The government on Friday launched diabetes drug Sitagliptin and its combinations at rates as low as Rs 60 per pack of ten, which will be sold at generic pharmacy stores, Janaushadhi Kendras. The Pharmaceuticals & Medical Devices Bureau of India (PMBI) has included new variants of Sitagliptin and its combination across its Jan Aushdhi Kendras, the Ministry of Chemicals and Fertilisers said in a statement. The maximum retail price for a pack of ten Sitagliptin phosphate tablets 50 mg is Rs 60, while the same for Sitagliptin phosphate tablet 100 mg is Rs 100. Combination of Sitagliptin and Metformin Hydrochloride tablets of 50mg/500mg is priced at Rs 65 for a pack of ten and Sitagliptin Metformin hydrochloride tablets of 50mg/1000mg strength comes for Rs 70 for the same quantity. "All these variants are available at 60 per cent to 70 per cent lesser prices than branded variants as they are available in price band of Rs 162 to Rs 258 at other medical stores," the statement said. PMBI

Controlling blood sugar level can predict risk to type 1 diabetics

New research states that blood sugar level should be lower than 53 mmol/mol (7%) to avoid health complications

New diabetes drug achieves blood sugar, weight targets faster: Research

T2D is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose in the blood

Control of blood sugar in mothers with diabetes better for infants: Study

Research led by Caroline Crowther of the University of Auckland, New Zealand, and a team, the findings were published in the journal PLOS Medicine

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Zydus Life launches generic version of Sitagliptin for type 2 diabetes

Zydus Lifesciences Ltd on Friday said it has launched the generic version of sitagliptin in India under the brand names Sitaglyn and Siglyn to address type 2 diabetes.

Going off-patent, key diabetes drug likely to get 50-70% cheaper

Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market

US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients

On Tuesday, the CDC, citing case reports and concerns that relapsed patients could spread the virus, issued its advisory that Paxlovid users should isolate for a second five days if symptoms rebound

Tech firm MFine helps people monitor blood pressure, glucose on smartphones

MFine has democratised health care at home by bringing these solutions on to devices that are more ubiquitous and affordable than wearables

Long Covid-induced diabetes, depression can be treated by exercise: Study

Though no medically recognized treatment exists for Long Covid, a study suggests that exercise might break cycle of inflammation that develops diabetes and depression months after a person recovers

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Pharma company Abbott ties up with health tech firms for diabetes care

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

India's diabetes care market to reach $60 bn in next 10 yrs: Report

The diabetes care market in India is expected to reach about $60 billion in the next 10 years, from approximately $17 billion in FY2021, a new report said

Statsguru: Obesity to diabetes, 6 charts explain health concerns for India

Data shows that obesity is increasingly growing among both men and women

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

IMA urges Covid vax, including booster dose if needed, for all diabetics

Noticing their vulnerabilities, IMA on Sunday demanded Covid-19 vaccination for all diabetes patients, including a third dose, if needed. The IMA on Sunday launched a campaign for early detection and mitigation of diabetes complications with organising of walkathon, marathon, screening camps, and a social media drive. The campaign also included research paper promotion among young doctors and an "intense" personal intervention at hospitals. The campaign, launched on the occasion of world Diabetes Day, will run for 10 days and will aim to reach one billion people, the Indian Medical Association (IMA) said in a statement. As part of the campaign, the IMA has joined hands with the association of Physicians of India, RSSDI, Endocrine Society, and many other niche organisations. As per the data from the 10th Edition of the IDF Diabetes Atlas, diabetes caused 6.7 million deaths in 2021, with 537 million adults (aged 20 to 79 years) around the world currently living with the condition.

Post-Covid fatigue is most prevalent in diabetes patients: Study

People with Type-2 diabetes who also suffered Covid-19 are more likely to experience severe fatigue than those who did not have the infectious disease, according to a new study released on Thursday

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

NPPA fixes price caps for 12 anti-diabetic medicines

These include glimepiride tablet of strength 1 mg, with ceiling price at Rs 3.6 per tablet, while that for 2 mg is Rs 5.72 per tablet